$ERNA News

Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center

Ernexa Therapeutic To Present New Preclinical Data From Its ERNA-101 Lead Oncology Program At The Next-Generation Cancer Therapeutics Meeting, October 6–8

Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic

Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND

Ernexa Therapeutics Announces Encouraging Results From Three Core IND-Enabling Safety Studies Of ERNA-101, Lead Synthetic, Allogeneic iMSC Therapy Engineered To Express IL-7/IL-15 Fusion Cytokine

Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy

Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors

Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing

Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies

Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy

Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)

Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry

Ernexa Therapeutics Announces Independently Conducted Study Validating Anti-Tumor Activity Of Its ERNA-101 Lead Cell Therapy Candidate Shows Complete Tumor Clearance, Durable Long-Term Survival; Investigational New Drug Submission Planned In Q3

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study